Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy
- PMID: 20969974
- PMCID: PMC3384750
- DOI: 10.1016/j.hrthm.2010.10.018
Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy
Abstract
Background: Defibrillation therapy for atrial fibrillation (AF) and flutter (AFl) is limited by pain induced by high-energy shocks. Thus, lowering the defibrillation energy for AFl/AF is desirable.
Objective: In this study we applied low-voltage multiple-shock defibrillation therapy in a rabbit model of atrial tachyarrhythmias comparing its efficacy to single shocks and antitachycardia pacing (ATP).
Methods: Optical mapping was performed in Langendorff-perfused rabbit hearts (n = 18). Acetylcholine (7 ± 5 to 17 ± 16 μM) was administered to promote sustained AFl and AF, respectively. Single and multiple monophasic shocks were applied within 1 or 2 cycle lengths (CLs) of the arrhythmia.
Results: We observed AFl (CL = 83 ± 15 ms, n = 17) and AF (CL = 50 ± 8 ms, n = 11). ATP had a success rate of 66.7% in the case of AFl, but no success with AF (n = 9). Low-voltage multiple shocks had 100% success for both arrhythmias. Multiple low-voltage shocks terminated AFl at 0.86 ± 0.73 V/cm (within 1 CL) and 0.28 ± 0.13 V/cm (within 2 CLs), as compared with single shocks at 2.12 ± 1.31 V/cm (P < .001) and AF at 3.46 ± 3 V/cm (within 1 CL), as compared with single shocks at 6.83 ± 3.12 V/cm (P =.06). No ventricular arrhythmias were induced. Optical mapping revealed that termination of AFl was achieved by a properly timed, local shock-induced wave that collides with the arrhythmia wavefront, whereas AF required the majority of atrial tissue to be excited and reset for termination.
Conclusion: Low-voltage multiple-shock therapy terminates AFl and AF with different mechanisms and thresholds based on spatiotemporal characteristics of the arrhythmias.
Copyright © 2011 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interest: IRE is a member of the Board of Directors and owns stock in Cardialen, Inc. CMA, CMR, IRE, and VVF are co-inventors on the patent entitled “Method and Device for Three-Stage Atrial Cardioversion Therapy”.
Figures








Comment in
-
Atrial defibrillation voltage: falling to a new low.Heart Rhythm. 2011 Jan;8(1):109-10. doi: 10.1016/j.hrthm.2010.10.037. Epub 2010 Oct 29. Heart Rhythm. 2011. PMID: 21044899 Free PMC article. No abstract available.
References
-
- Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125. - PubMed
-
- Crandall MA, Horne BD, Day JD, et al. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. Pacing Clin Electrophysiol. 2009;32(8):981–986. - PubMed
-
- Seiler J, Stevenson WG. Atrial fibrillation in congestive heart failure. Cardiol Rev. 2010;18(1):38–50. - PubMed
-
- Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954–1968. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical